FDA is on the lookout for the effects of personalized medicine on the orphan drug program and the potential for all diseases to be defined in such a way that they become eligible for orphan status.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?